Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

27.22 +0.75 (+2.83%)
Streaming Delayed Price Updated: 12:32 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Celldex Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Analyst Expectations For Celldex Therapeutics's Future
 
Via Benzinga
Technical Breakout Setup for CELLDEX THERAPEUTICS INC (NASDAQ:CLDX)
CLDX stock shows strong technical momentum and a high-quality consolidation pattern, suggesting a potential breakout above the $26.20 resistance level. 
Via Chartmill
5 Analysts Assess Celldex Therapeutics: What You Need To Know
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short
Celldex will stop developing barzolvolimab in eosinophilic esophagitis after Phase 2 data showed strong mast cell reduction but no symptom improvement. 
Via Benzinga
Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics
 
Via Benzinga
Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews
 
Via Benzinga
What Analysts Are Saying About Celldex Therapeutics Stock
 
Via Benzinga
What Analysts Are Saying About Celldex Therapeutics Stock
 
Via Benzinga
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock
 
Via Benzinga
Analyst Expectations For Celldex Therapeutics's Future
 
Via Benzinga
Why Are Celldex Shares Tumbling After Hours?
The biotech firm said it would halt development of barzolvolimab in eosinophilic esophagitis following Phase 2 results that met the trial’s primary goal but failed to show clinical benefit. 
Via Stocktwits
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
These stocks are moving in today's after hours session
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Celldex Therapeutics Inc (NASDAQ:CLDX) Q2 2025 Earnings: Revenue Misses, EPS Narrowly Beats Amid Strong Pipeline Progress
Celldex Therapeutics Q2 2025 earnings: Revenue misses estimates at $730K, but EPS beats at -$0.85. Strong cash position supports pipeline, with key barzolvolimab trials progressing. 
Via Chartmill
Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded
Celldex’s candidate targets KIT, a mast cell receptor tied to CSU inflammation, and had earlier met all key endpoints at 12 weeks. 
Via Stocktwits
Crude Oil Rises 6%; US Consumer Sentiment Surges In June
 
Via Benzinga
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Forecasting The Future: 8 Analyst Projections For Celldex Therapeutics
 
Via Benzinga
Analyst Expectations For Celldex Therapeutics's Future
 
Via Benzinga
This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
7 Analysts Have This To Say About Celldex Therapeutics
 
Via Benzinga
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Baidu, Informatica And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors
Jasper Therapeutics reports strong briquilimab efficacy in CSU with UAS7 reductions, dose-dependent responses, and Phase 2b plans by late 2025. 
Via Benzinga
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.